Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OCS Stock Forecast 2026-2027
$27.46
Current Price
$1.59B
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to OCS Price Targets
+105.5%
To High Target of $56.43
+80.1%
To Median Target of $49.45
+38.7%
To Low Target of $38.10
OCS Price Momentum
-0.5%
1 Week Change
+10.5%
1 Month Change
+51.5%
1 Year Change
+37.5%
Year-to-Date Change
-10.5%
From 52W High of $30.68
+71.6%
From 52W Low of $16.00
📊 TOP ANALYST CALLS
Did OCS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Oculis is one of their latest high-conviction picks.
Latest OCS Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, OCS has a bullish consensus with a median price target of $49.45 (ranging from $38.10 to $56.43). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $27.46, the median forecast implies a 80.1% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OCS Analyst Ratings
9
Buy
0
Hold
0
Sell
OCS Price Target Range
Low
$38.10
Average
$49.45
High
$56.43
Current: $27.46
Latest OCS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OCS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 5, 2026 | Stifel | Annabel Samimy | Buy | Maintains | $50.00 |
| Mar 4, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $44.00 |
| Mar 4, 2026 | Needham | Serge Belanger | Buy | Maintains | $40.00 |
| Dec 19, 2025 | Stifel | Annabel Samimy | Buy | Maintains | $40.00 |
| Dec 19, 2025 | JP Morgan | Tessa Romero | Overweight | Initiates | $38.00 |
| Dec 3, 2025 | LifeSci Capital | Outperform | Initiates | $55.00 | |
| Nov 13, 2025 | B of A Securities | Jason Gerberry | Buy | Maintains | $29.00 |
| Nov 11, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $51.00 |
| Nov 11, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $42.00 |
| Nov 11, 2025 | Needham | Serge Belanger | Buy | Reiterates | $36.00 |
| Oct 8, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $51.00 |
| Oct 7, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $36.00 |
| Aug 27, 2025 | Needham | Serge Belanger | Buy | Initiates | $36.00 |
| Aug 22, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $33.00 |
| May 9, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $33.00 |
| Apr 17, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $28.00 |
| Apr 17, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $32.00 |
| Mar 13, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $29.00 |
| Mar 13, 2025 | Baird | Colleen Kusy | Outperform | Maintains | $41.00 |
| Mar 13, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $28.00 |
Oculis Holding AG (OCS) Competitors
The following stocks are similar to Oculis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Oculis Holding AG (OCS) Financial Data
Oculis Holding AG has a market capitalization of $1.59B with a P/E ratio of 63.6x. The company generates $1.54M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +13,600.0% quarter-over-quarter, while maintaining an operating margin of -5,020.2% and return on equity of -73.5%.
Valuation Metrics
Market Cap
$1.59B
Enterprise Value
$1.77B
P/E Ratio
63.6x
PEG Ratio
-1.7x
Price/Sales
1,328.0x
Growth & Margins
Revenue Growth (YoY)
+13,600.0%
Gross Margin
N/A
Operating Margin
-5,020.2%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+13.4%
Current Ratio
6.0x
Debt/Equity
1.2x
ROE
-73.5%
ROA
-28.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Oculis Holding AG (OCS) Business Model
About Oculis Holding AG
What They Do
Develops innovative ophthalmic therapies for eye care.
Business Model
Oculis Holding AG generates revenue through the development and commercialization of advanced ophthalmic therapies. The company focuses on creating effective drug delivery systems that address significant unmet medical needs in eye care, targeting various eye diseases such as dry eye syndrome and diabetic macular edema.
Additional Information
Oculis is heavily invested in research and development to improve treatment efficacy and accessibility for patients with chronic and acute eye conditions. As a publicly traded company, it plays a vital role in the biotechnology sector, influencing advancements and trends in the global eye care market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
60
CEO
Dr. Riad Sherif M.B.A., M.D.
Country
Switzerland
IPO Year
2023
Website
oculis.comOculis Holding AG (OCS) Latest News & Analysis
Latest News
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
12 days ago
Quick Summary
On April 8, 2026, it was announced that a director of the Company will have their Restricted Stock Units (RSUs) vested and settled.
Why It Matters
The vesting of RSUs for a director signals potential changes in insider ownership and alignment with shareholder interests, impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oculis Holding AG will participate in investor conferences in April 2026. The company focuses on innovations for ophthalmic and neuro-ophthalmic diseases.
Why It Matters
Oculis' participation in investor conferences signals potential growth and innovation, attracting attention from investors looking for opportunities in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oculis Holding AG's neuroprotective candidate, Privosegtor, received PRIME designation from the EMA for treating optic neuritis, a rare condition linked to multiple sclerosis.
Why It Matters
The PRIME designation for Oculis's Privosegtor enhances its market potential, signaling strong regulatory support and possibly accelerating development, which can drive stock value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oculis Holding AG (Nasdaq: OCS) presented Phase 2 data for Privosegtor at the NANOS 52nd Annual Meeting, focusing on innovations in ophthalmology and neuro-ophthalmology.
Why It Matters
The announcement of positive Phase 2 data for Privosegtor could enhance Oculis's market position, attract investment, and influence stock performance due to potential future revenue from new treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oculis Holding AG reported financials for Q4 and FY 2025, highlighting key milestones, including Phase 3 trial results expected in Q2 2026 and a $7 billion market opportunity in optic neuropathies. The company holds $268.7 million in cash, ensuring funding until 2029.
Why It Matters
Oculis Holding AG's advancements in clinical trials and strong cash position signal potential for significant revenue growth, especially in a lucrative market like neuro-ophthalmology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oculis Holding AG (OCS) reported a quarterly loss of $0.51 per share, worse than the expected loss of $0.43, but an improvement from a loss of $0.76 per share a year earlier.
Why It Matters
Oculis Holding AG's larger-than-expected quarterly loss raises concerns about financial performance, potentially impacting stock sentiment and future investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About OCS Stock
What is Oculis Holding AG's (OCS) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Oculis Holding AG (OCS) has a median price target of $49.45. The highest price target is $56.43 and the lowest is $38.10.
Is OCS stock a good investment in 2026?
According to current analyst ratings, OCS has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $27.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OCS stock?
Wall Street analysts predict OCS stock could reach $49.45 in the next 12 months. This represents a 80.1% increase from the current price of $27.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Oculis Holding AG's business model?
Oculis Holding AG generates revenue through the development and commercialization of advanced ophthalmic therapies. The company focuses on creating effective drug delivery systems that address significant unmet medical needs in eye care, targeting various eye diseases such as dry eye syndrome and diabetic macular edema.
What is the highest forecasted price for OCS Oculis Holding AG?
The highest price target for OCS is $56.43 from at , which represents a 105.5% increase from the current price of $27.46.
What is the lowest forecasted price for OCS Oculis Holding AG?
The lowest price target for OCS is $38.10 from at , which represents a 38.7% increase from the current price of $27.46.
What is the overall OCS consensus from analysts for Oculis Holding AG?
The overall analyst consensus for OCS is bullish. Out of 9 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $49.45.
How accurate are OCS stock price projections?
Stock price projections, including those for Oculis Holding AG, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 6:20 PM UTC